There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BeiGene (BGNE – Research Report) and Travere Therapeutics (TVTX – Research Report) with bullish sentiments.
BeiGene (BGNE)
TD Cowen analyst Yaron Werber maintained a Buy rating on BeiGene today and set a price target of $224.00. The company’s shares closed last Wednesday at $160.70, close to its 52-week low of $153.13.
According to TipRanks.com, Werber is a 5-star analyst with an average return of
Currently, the analyst consensus on BeiGene is a Moderate Buy with an average price target of $253.45, a 54.5% upside from current levels. In a report issued on January 10, Jefferies also maintained a Buy rating on the stock with a $287.00 price target.
See today’s best-performing stocks on TipRanks >>
Travere Therapeutics (TVTX)
In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on Travere Therapeutics, with a price target of $15.00. The company’s shares closed last Wednesday at $9.06.
According to TipRanks.com, Buren is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Travere Therapeutics with a $14.20 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BGNE:
